MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/curroncol33090510

Медицинская библиотека · Current oncology (Toronto, Ont.) · 2026

Tolerance and Efficacy of Targeted Therapies After Immunotherapy for Advanced Non-Small Cell Lung Cancers Harboring Oncogenic Alterations: The GFPC-TOXIMAD Study.

Pierret Thomas, Auliac Jean-Bernard, Ricordel Charles, Daniel Catherine, Nguyen Jessica, Guisier Florian, Swalduz Aurélie, Curcio Hubert, Desage Anne Laure, Bigay-Game Laurence, Huchot Eric, Falchero Lionel, Doubre Hélène, Bylicki Olivier, Chouaïd Christos, Greillier Laurent

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПеревод в очереди

Аннотация

BACKGROUND

The sequential use of anti-programmed cell death (ligand)-1 [PD-(L)1] immune-checkpoint inhibitors (ICIs) followed by targeted tyrosine-kinase inhibitors (TKIs) for advanced non-small cell lung cancer (NSCLC) with oncogenic alterations raises questions about tolerance and efficacy. Recent study results suggested an increased risk of adverse events (AEs) with this sequence.

METHODS

Multicenter retrospective study on advanced NSCLC patients treated with ICIs followed by targeted therapies between 2015 and 2021. The primary endpoint was the rate of grade 3-5 adverse events (AEs). Main secondary endpoints were progression-free survival (PFS), time-to-treatment failure and overall survival (OS).

RESULTS

The analysis included 109 patients (most with EGFR, 30.3%; BRAF, 17.4%; MET exon-14, 17.4%; ALK, 10.1%; and RET, 6.4% gene alterations); 28/109, which is 25.7% of the patients, experienced grade 3/4 AEs and 4/109 (3.7%) experienced grade 5 AEs, leading to the definitive cessation of targeted therapy treatment in 14/32 (44%) of cases; higher grade 3-5 rates were observed with the dabrafenib-trametinib combination (12/16, 75%), capmatinib (4/8, 50%) and crizotinib (8/16, 50%). A last ICI-administration-to-targeted therapy-start interval of <90 days appeared to be associated with grade ≥ 3 AEs (32/82, 39% vs. 0/27 p = 0.001). In these sequential strategies, effectiveness of targeted therapies, in this second-line or later setting, appears to be lower than that in the published historical data.

CONCLUSION

According to this analysis, sequential ICI-targeted therapy use for advanced NSCLC appeared to be associated with more grade 3-5 AEs.

Для цитирования: Pierret Thomas, Auliac Jean-Bernard, Ricordel Charles, Daniel Catherine, Nguyen Jessica, Guisier Florian, Swalduz Aurélie, Curcio Hubert, Desage Anne Laure, Bigay-Game Laurence, Huchot Eric, Falchero Lionel, Doubre Hélène, Bylicki Olivier, Chouaïd Christos, Greillier Laurent. Tolerance and Efficacy of Targeted Therapies After Immunotherapy for Advanced Non-Small Cell Lung Cancers Harboring Oncogenic Alterations: The GFPC-TOXIMAD Study.. Current oncology (Toronto, Ont.). 2026. DOI: 10.3390/curroncol33090510.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.